QVF

Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings

产品代码
QVF
器械名称
Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings
管理类别
第 2 类(Class II)
21 CFR 条款
21 CFR 866.3982
FDA 专业组
Microbiology
上市路径
需提交 510(k) 上市前通告
该代码近三年的 510(k)
8 件
其中 Summary 已存档
6 份,可直接下载
FDA 历史累计 510(k)
9 件(全部年份;本站只收录近三年的明细)

FDA 分类定义

A simple point-of-care device to detect SARS-CoV-2 viral targets directly from clinical specimens in near-patient settings is an in vitro diagnostic device for the direct detection of SARS-CoV-2 in clinical specimens and is intended as an aid in the diagnosis of SARS-CoV-2 infections COVID-19). The device is simple to use and does not involve sample manipulation, transportation of the sample to another functional area (e.g., a central laboratory or other specialized area), or measurement of reagents or analytes that could be affected by conditions such as sample turbidity or cell lysis. The design and procedures of the device are appropriate for use by healthcare professionals in near-patient settings outside a centralized laboratory

定义原文来自 FDA 器械分类库,属美国联邦政府作品(公有领域)。

该代码近三年的 510(k)(8 件)

数据窗口为最近三年。最新一件:2026-06-01。

510(k) 号批准日期申请人器械名称摘要
K2538822026-06-01CorDx, Inc.CorDx Tyfast COVID-19 Ag Rapid Test RxPDF
K2512892025-10-22Guangzhou Wondfo Biotech Co., Ltd.WELLlife COVID-19 Antigen Test RxFDA
K2438722025-06-16Becton, Dickinson and CompanyBD Veritor System for SARS-CoV-2PDF
K2502732025-06-13Abbott Diagnostics Scarborough, Inc.BinaxNOW COVID-19 Ag CardPDF
K2333582024-08-23InBios International, Inc.SCoV-2 Ag Detect Rapid Test
K2323772024-04-19Healgen Scientific,, LLCHealgen Rapid COVID-19 Antigen TestPDF
K2311872024-01-23Nano-Ditech CorporationNano-Check™ COVID-19 Antigen TestPDF
K2336882023-12-13Quidel CorporationSofia 2 SARS Antigen+ FIA; Sofia 2 SARS Antigen+ FIA…PDF

其中 6 件的 Summary 已存档在本站,点 PDF 直接下载;其余给 FDA 官方链接。

FDA 官方分类页: QVF
分类与上市路径以 FDA 现行公告为准。本页数据来自 openFDA(CC0 公有领域),不构成注册策略建议。